P159: Inhibition of Caspase-1 signalling subtly affect the gut microbiota and reduces Adherent-invasive Escherichia coli (AIEC)-induced inflammasome activationECCO'24Year: 2024
Authors: Barrett, K.(1);Aguilera, M.(1);Manning, C.(1);O@E@Sullivan, O.(2);Clarke, D.(3);MelgarPhD, S.(1)*;
(1)University College Cork, APC Microbiome Ireland, Cork City, Ireland;(2)Teagasc Food Research Centre, APC Microbiome Ireland, Fermoy, Ireland;(3)University College Cork, School of Microbiology, Cork City, Ireland;
P160: Integrative transcriptional analysis to identify predictive biomarkers for IBD severity and subtypingECCO'24Year: 2024
Authors: Balasubramanian, B.(1);Patel, S.(1);Gall, L.(2);Parker, S.(1);Carpenter, A.(1);Hannan, N.(1);Pin, C.(2);Moran, G.(3);Ordóñez Morán, P.(4)*;
(1)University of Nottingham- School of Medicine, Translational Medical Sciences, Nottingham, United Kingdom;(2)AstraZeneca, Clinical Pharmacology & Quantitative Pharmacology, Cambridge, United Kingdom;(3)Nottingham Digestive Diseases Centre- University of Nottingham- School of Medicine, Biomedical Research Unit, Nottingham, United Kingdom;(4)University of Nottingham- School of Medicine, Translational Medical Sciences Unit, Nottingham, United Kingdom;Basic Science
P161: Prevalence of undernutrition in patients with inflammatory bowel disease and improvement after nutritional adviceECCO'24Year: 2024
Authors: Kutar, M.(1);Dharap, V.(2);Dhoble, P.(2)*;Trinidade, S.(3);Gupta, T.(2);Abraham, P.(2);Desai, D.(2);
(1)P. D Hinduja National Hospital and Medical Research Center, Medical Gastroenterology, Mumbai, India;(2)P. D Hinduja National Hospital & Medical Research Institute- Mumbai, Medical Gastroenterology, Mumbai, India;(3)P. D Hinduja National Hospital & Medical Research Institute- Mumbai, Dietician, Mumbai, India;
P161: The use of Novel Natural Treatments for Inflammatory Bowel DiseasesECCO'24Year: 2024
Authors: Najafzadeh, M.(1)*;
(1)University of bradford, Chemistry and BioSciences, Bradford, United Kingdom;Mojgan Najafzadeh1* Zahra Adoul1 Shohreh Jafarinejad1 Adi Baumgartner2 Domenic Reynolds3 Mohammad Isreb4 Rojan Ghaderi5 Farshid Sefat6 Saeed Heidari 7 Diana Anderson1 1 School of Life Sciences Chemistry and Biosciences Department University of Bradford Bradford BD7 1DP UK 2 School of Science Technology and Health Biosciences York St John University York YO31 7EX UK 3Bradford Teaching Hospitals NHS Foundation Trust Bradford Royal Infirmary Bradford UK 4Faculty of Life Sciences School of Pharmacy and Medical Sciences University of Bradford Bradford BD7 1DP UK 5Department of Medicine Imperial College London London SW7 2BX 6 Department of Biomedical and Electronics Engineering Faculty of Engineering and Informatics University of Bradford Bradford UK 7 Cell Therapy and Tissue Engineering Department Faculty of Medical Sciences Shahid Beheshti University Tehran Iran
P162: Upadacitinib in Crohn’s Disease Patients: for what type of patients in real world setting ?ECCO'24Year: 2024
Authors: JuilleratMSc, P.(1,2,3)*;Martinho-Grueber , M.(1,2);Ruetsch, R.(2);Moubayed, H.(1);Vullièmoz-, M.(1);Michetti. , P.(1,4);
(1)Crohn and Colitis center- GEB La Source Beaulieu, Gastroenterology, Lausanne, Switzerland;(2)Gastroenterology center- Bulle, Gastroenterology, Bulle, Switzerland;(3)Bern University Hospital., Clinic for Visceral Surgery and Medicine-, Bern, Switzerland;(4)Lausanne University Hospital- CHUV, Gastroenterology, Lausanne, Switzerland;
P163: Incidence and risk of hip replacement rate in patients with inflammatory bowel disease in Taiwan:ECCO'24Year: 2024
Authors: Lai, H.C.(1);Wu, Y.H.(2)*; Wang, C.P.(2);Huang, P.J.(2);Cheng, K.S.(2);Chou, J.W.(2);
(1)School of Chinese Medicine- China Medical University- Taiwan, Graduate Institute of Chinese Medicine, Taichung, Taiwan;(2)China Medical University Hospital- Taiwan, Center for Digestive Medicine- Department of Internal Medicine, Taichung, Taiwan;
P164: Early monitoring of ustekinumab concentration after induction is related to clinical remission in ulcerative colitis & Crohn`s disease - STOCUSTE studyECCO'24Year: 2024
Authors: Sabhan, H.(1)*;
(1)St: Görans hospital, Internal Medicine / Gastroenterology, Kista, Sweden;F Johansson3 F Bello4 C Wennerström5 O Forsberg5 A Borin6 S Almer7 C Höög8 C Söderman2 M Lördal M1 1 1 Division of Gastroenterology and Hepatology Department of Medicine Danderyd Hospital Danderyd Sweden 2 4 Gastroenterology Unit Medical Department S:t Göran’s Hospital Stockholm Sweden 3 2 Medical library at Danderyd Hospital Danderyd Sweden 4 3 Division of Gastroenterology Karolinska university hospital Stockholm Sweden 5 5 Janssen Cilag AB Stockholm Sweden 6 6 Department of Medicine South Hospital Stockholm Sweden 7 8 Department of Medicine Solna Karolinska Institutet Stockholm Sweden 8 7 Department of Medicine Huddinge Karolinska Institutet Stockholm Sweden
P164: MRT-6160, a VAV1-directed molecular glue degrader, inhibits disease progression and inflammation in a T-cell transfer model of Colitis.ECCO'24Year: 2024
Authors: CartwrightPh.D, A.(1);Desai, F.(2);Nguyen, S.(3);Trouilloud, A.(2);Vora, S.(2);Gyger, L.(1);Roditi, L.(4);Lam, D.(5);Trenh, P.(6);Lucas, X.(4);Zlotosch, M.(5);Liardo, E.(7);Wible, D.(2);Oleinikovas, V.(4);Lamberto, I.(5);Demarco, B.(8);King, C.(3);Bonenfant, D.(9);Townson, S.(10);Wallace, O.(2);Krishnan, E.(11);De Beukelaer, S.(12)*;Janku, F.(11);McAllister, L.(7);Paterson, A.(2);Peluso, M.(2);
(1)Monte Rosa Therapeutics, Target and Discovery Biology, Basel, Switzerland;(2)Monte Rosa Therapeutics, Target and Discovery Biology, Boston, United States;(3)Monte Rosa Therapeutics, Nonclinical Development and Clinical Pharmacology, Boston, United States;(4)Monte Rosa Therapeutics, Data Sciences, Basel, Switzerland;(5)Monte Rosa Therapeutics, Automation and Screening, Boston, United States;(6)Monte Rosa Therapeutics, Structural Biology, Boston, United States;(7)Monte Rosa Therapeutics, Chemistry, Basel, Switzerland;(8)Monte Rosa Therapeutics, Discovery Technologies, Boston, United States;(9)Monte Rosa Therapeutics, Proteomics, Basel, Switzerland;(10)Monte Rosa Therapeutics, Biomolecular Sciences, Boston, United States;(11)Monte Rosa Therapeutics, Clinical Development, Boston, United States;(12)Monte Rosa Therapeutics, Clinical Development, Basel, Switzerland;
P165: Epidemiology and distinct features of inflammatory bowel disease in South Asia: a systematic reviewECCO'24Year: 2024
Authors: Shenoy, S.(1,2)*;Jena, A.(3);Levinson, C.(4);Sharma, V.(2,5);Deepak, P.(2,6);Aswani-Omprakash, T.(2);Sebastian, S.(2,7);Colombel, J.F.(8);Agrawal, M.(8,9);
(1)Mount Sinai Morningside Hospital, Department of Medicine, New York, United States;(2)South Asian IBD Alliance SAIA, South Asian IBD Alliance SAIA, New York, United States;(3)Institute of Medical Sciences and SUM Hospital, Department of Gastroenterology, Bhubaneshwar, India;(4)Icahn School of Medicine at Mount Sinai, Levy Library, New York, United States;(5)Post Graduate Institute of Medical Education and Research, Department of Gastroenterology, Chandigarh, India;(6)Washington University in St. Louis School of Medicine, IBD center- Division of Gastroenterology, St. Louis, United States;(7)Hull University Teaching Hospitals, IBD unit, Hull HU3 2JZ, United Kingdom;(8)Icahn School of Medicine at Mount Sinai, The Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;(9)Center for Molecular Prediction of Inflammatory Bowel Disease PREDICT- Aalborg University, Department of Clinical Medicine, Copenhagen, Denmark;
P165: Guselkumab binding to CD64+ IL-23–producing myeloid cells enhances potency for neutralizing IL-23 signaling.ECCO'24Year: 2024
Authors: Atreya, R.(1)*;Abreu, M.T.(2);Krueger, J.G.(3);Eyerich, K.(4,5);Greving, C.(6);Hammaker, D.(6);Stoveken, B.(7);Hartman, J.(7);Leppard, K.(8);Sarabia, I.(6);Wertheimer, J.(8);Deming, J.(6);Kohler, K.(9);Li, H.(10);Freeman, T.(10);Hart, A.(10);Keyes, B.(11);Ritchlin, C.(12);McInnes, I.B.(13);Allez, M.(14);Fourie, A.(6);Sachen, K.(6);
(1)Erlangen University Hospital- Friedrich-Alexander-Universität Erlangen-Nürnberg, Department of Medicine 1, Erlangen, Germany;(2)University of Miami, Leonard Miller School of Medicine, Miami FL, United States;(3)The Rockefeller University, Laboratory for Investigative Dermatology, New York- NY, United States;(4)University of Freiburg, Medical Center, Freiburg, Germany;(5)Karolinska Institute, Department of Medicine – Division of Dermatology and Venereology, Stockholm, Sweden;(6)Janssen Research & Development LLC, Immunology, San Diego CA, United States;(7)Janssen Research & Development LLC, Computational Biology, Spring House PA, United States;(8)Janssen Research & Development LLC, Immunology, Spring House PA, United States;(9)Janssen Research & Development LLC, Statistics & Decision Science, San Diego CA, United States;(10)Janssen Research & Development LLC, Translational Science, Spring House PA, United States;(11)Janssen Research & Development LLC, Translational Science, San Deigo CA, United States;(12)University of Rochester, Department of Medicine - Allergy/Immunology and Rheumatology, Rochester NY, United States;(13)University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom;(14)Hôpital Saint-Louis, Université Paris Cité, Paris, France;
P166: Optimizing PD-1 agonist signaling with membrane proximal binding of rosnilimab, a clinical stage PD-1 agonist IgG1 antibodyECCO'24Year: 2024
Authors: Parmley, S.(1);Szlyk, B.(1);Frank, R.T.(1);Hsu, M.(1);Brodsky, P.(1);Sibley, C.(2);Lizzul, P.(2);Dahl, M.(1)*;
(1)AnaptysBio- Inc, Research, San Diego, United States;(2)AnaptysBio- Inc, Clinical, San Diego, United States;
P166: Thiopurines and Risk of Cancer in Patients with Inflammatory Bowel Disease -A Danish Nationwide Cohort study 1996-2018ECCO'24Year: 2024
Authors: Wewer, M.D.(1,2)*;Letnar, G.(3);Andersen, K.K.(3);Malham, M.(2,4,5);Wewer, V.(2,4,6);Seidelin, J.B.(6,7);Bendtsen, F.(1,2,6);Burisch, J.(1,2);
(1)Hvidovre Hospital- University of Copenhagen, Gastro Unit- Medical Division, Hvidovre, Denmark;(2)Hvidovre Hospital- University of Copenhagen, Copenhagen Center for Inflammatory Bowel Disease in Children- Adolescents and Adults, Hvidovre, Denmark;(3)Omicron ApS, Omicron ApS, Copenhagen, Denmark;(4)Hvidovre Hospital- University of Copenhagen, The Department of Paediatrics and Adolescent Medicine, Hvidovre, Denmark;(5)Boston University School of Public Health- Boston, Departments of Epidemiology and Global Health, Boston, United States;(6)University of Copenhagen, Department of Clinical Medicine, Copenhagen, Denmark;(7)Herlev Hospital- University of Copenhagen, Department of Gastroenterology, Herlev, Denmark;
P167: Inflammatory Bowel Disease: a phenome-wide pre- and post-diagnostic association studyECCO'24Year: 2024
Authors: Ebert, A.(1);ElmahdiMBBS- PhD, R.(1,2)*;Poulsen, G.(1);Bøgsted, M.(1);Verstockt, B.(3,4);Lees, C.(5);Jess, T.(1,6);
(1)National Center of Excellence for the Molecular Prediction of IBD, Clinical Medicine- Aalborg University, Copenhagen, Denmark;(2)Aalborg University Hosptial, Gastroenterology and Hepatology, Aalborg, Denmark;(3)University Hosptials Leuven, Gastroloenterology and Hepatology, Leuven, Belgium;(4)KU Leuven, Chronic Diseases and Metabolism, Leuven, Belgium;(5)Centre for Genomic and Experimental Medicine, Institue of Genetics and Cancer- University of Edinburgh, Edinburgh, United Kingdom;(6)Aalborg University Hospital, Gastroenterology and Hepatology, Aalborg, Denmark;
P168: Specialized pro-resolving lipid mediator Resolvin D1 and omega 6 dihomo-γ-linolenic acid are unable to solve inflammation in the creeping fat of patients with severe postoperative recurrence in Crohn@E@s disease.ECCO'24Year: 2024
Authors: Suau, R.(1)*;Pardina, E.(2);Clua, L.(1);Cordobilla, B.(2);Zabana, Y.(3,4);Calafat, M.(1,4,5);Carmona-Maurici, J.(2);Guasch, M.(6);Lorén, V.(1);Ricart-Jané, D.(2);Viñas-Calaf, A.(2);Fluvià, L.(7);Aguilar, R.(8);Mañosa, M.(1,4,5);Dobaño, C.(8,9);Hernández, J.M.(7);López-Tejero, M.D.(2);Domingo, J.C.(2);Domènech, E.(1);Serena, C.(10);Manyé, J.(1,4);
(1)Germans Trias i Pujol Research Institute IGTP, IBD Research Group, Badalona, Spain;(2)University of Barcelona, Biochemistry and Molecular Biomedicine Department, Barcelona, Spain;(3)MútuaTerrassa University Hospital, Digestive System Service, Terrassa, Spain;(4)Centro de Investigación Biomédica en Red CIBER, Enfermedades Hepáticas y Digestivas CIBEREHD, Madrid, Spain;(5)University Hospital Germans Trias i Pujol HUGTP, Digestive Tract Service, Badalona, Spain;(6)Hospital Parc Sanitari Sant Joan de Déu, Departament de Cirurgia, Sant Boi de Llobregat, Spain;(7)IGTP, Proteomics and Metabolomics Unit, Badalona, Spain;(8)Institute for Global Health ISGLOBAL- University of Barcelona- Hospital Clínic, Malaria Immunology Research Group, Barcelona, Spain;(9)CIBER, CIBER Enfermedades Infecciosas, Barcelona, Spain;(10)Institut d@E@Investigació Sanitària Pere Virgili IISPV, Inflammatory Bowel Disease IBODI Research Group, Tarragona, Spain;
P169: Circulating eNAMPT predicts anti-TNF response in IBD patients: possible place in therapy of anti-eNAMPT antibodyECCO'24Year: 2024
Authors: TravelliPh.D, C.(1)*;Cascetta, G.(2);colombo, G.(3);Alessi, A.(2);Caputo, E.(2);Lenti, M.V.(4);Pasini, A.(4);Porta , C.(3);Ribaldone, D.(5);Pastorelli, L.(6);Di Sabatino, A.(7);Genazzani, A.(3);Caviglia, G.P.(8);Stocco, G.(9);
(1)Università degli Studi di Pavia, Dipartimento di Scienze del Farmaco, pavia, Italy;(2)Università di Pavia, Scienze del Farmaco, Pavia, Italy;(3)Università del Piemonte Orientale, scienze farmaceutiche, Novara, Italy;(4)Università di Pavia, Medicina Interna, Pavia, Italy;(5)Università di Torino, Surgical Sciences, Torino, Italy;(6)IRCCS Policlinico San Donato, San Donato, Milano, Italy;(7)IRCCS San Matteo, Medicina Interna, Pavia, Italy;(8)Università di Torino, Scienze Mediche, Torino, Italy;(9)Università di Trieste, Life Sciences, Trieste, Italy;
P169: Multimorbidity and Disease Trajectories in Patients with INFLAMMATORY BOWEL DISEASES: Insights from Observational and Genetic AnalysesECCO'24Year: 2024
Authors: Jiang, F.(1)*;Zhao, J.(1);Chen, J.(1);Wang, L.(2);Yuan, S.(3);Kalla, R.(4);Wellens, J.(5);Nowak, J.(6);Larrson, S.(3);Ludvigsson, J.(7);Satsangi, J.(8);Theodoratou, E.(2);Li, X.(1);
(1)Zhejiang University School of Medicine, Department of Big Data in Health Science School of Public Health and The Second Affiliated Hospital, Hangzhou, China;(2)University of Edinburgh, Centre for Population Health Sciences- Usher Institute, Edinburgh, United Kingdom;(3)Karolinska Institutet, Unit of Cardiovascular and Nutritional Epidemiology- Institute of Environmental Medicine, Stockholm, Sweden;(4)University of Edinburgh, Department of Gastroenterology- Royal Infirmary of Edinburgh, Edinburgh, United Kingdom;(5)Translational Research Center for Gastrointestinal Disorders TARGID, KU Leuven Department of Chronic Diseases and Metabolism, Leuven, Belgium;(6)Poznan University of Medical Sciences, Department of Paediatric Gastroenterology and Metabolic Diseases, Poznan, Poland;(7)Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, Sweden;(8)University of Oxford, Translational Gastroenterology Unit- Nuffield Department of Medicine- Experimental Medicine Division, Oxford, United Kingdom;
